findmyKOL

Daniel Cantillon, MD

Enriched profile

Chief Medical Officer & Senior Vice President, Masimo Corporation · Masimo Corporation

ORCIDNPI
Region🇺🇸 Cleveland, OH · Midwest · United StatesSpecialtyCardiovascular DiseaseFocusHeart Failure
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2019Online presenceNone verifiedPayments2021–2024NIH fundingNone on fileWhy? →

Daniel Cantillon is Chief Medical Officer & Senior Vice President, Masimo Corporation at Masimo Corporation. OpenAlex indexes 167 publications with 6,061 citations (h-index 35); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Daniel Cantillon, MD, is Chief Medical Officer & Senior Vice President, Masimo Corporation. The public record shows 167 publications with 6,061 citations (h-index 35), centered on Heart Failure. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 7 companies.

  • Most recent indexed publication: 2019 · Clinical cardiology
  • Top research focus: Heart Failure
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 7 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Hypercapnia1 trialAtrial Fibrillation1 trialArrhythmias, Cardiac1 trialHeart Failure1 trialHeart Failure, Systolic1 trial

Research focus

OpenAlex concept fingerprint
Heart Failure

Works with

trial sponsors and companies reporting payments
Abbott LaboratoriesClinical trialsIndustry payments64Boston Scientific CorporationClinical trialsIndustry payments61Masimo CorporationClinical trialsIndustry payments20

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
167publications

Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.

6,061citations

Total citations across indexed works.

35h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials
7companies · 2021–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Public positions

sourced statements on record
  • Co-Chair

    Health Policy Committee, American College of Cardiology Ohio Chapter (professional-society health-policy role; no government testimony identified)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biography.omicsonline.org

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

7 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    57.3%
    Factor Xa inhibitor57.3%
    Eliquis80%Xarelto20%
    Part D<11 patients
  • Cardiovascular

    42.7%
    Beta blocker21.6%
    Metoprolol Succinate76%Nadolol25%
    Part D<11 patients
    Antiarrhythmic21.1%
    Flecainide Acetate52%Dofetilide25%Amiodarone Hcl23%
    Part D<11 patients
Where care is delivered (Part B), 202289.3% facility · 10.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    consultqd.clevelandclinic.org/clinical-trial-of-first-dual-chamber-leadless-pacemaker-underway

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →consultqd.clevelandclinic.org
  • X / Twitter

    X/Twitter: @djcantillonmd

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com
  • LinkedIn

    LinkedIn: Daniel Cantillon M.D. - Masimo

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Two terms

    Board of Trustees, American College of Cardiology - Ohio Chapter; Co-Chair, Health Policy Committee (historic)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biography.omicsonline.org
  • Principal investigator

    first-in-human leadless pacemaker-defibrillator study, Cleveland Clinic

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ideastream.org

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.